24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TROMLIEVA 25MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TROMLIEVA 25MG |
|---|---|
| Composition | Eltrombopag Olamine Tablets 25mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (4 x 7) |
| Country of Origin | India |
TROMLIEVA 25MG (Eltrombopag Olamine Tablets 25mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TROMLIEVA 25 MG (Eltrombopag Olamine Tablets 25 mg) is a prescription medicine containing Eltrombopag Olamine 25 mg, a thrombopoietin receptor agonist used to increase platelet production in patients suffering from certain blood disorders associated with low platelet counts. It is commonly prescribed for the treatment of Chronic Immune Thrombocytopenia (ITP), Severe Aplastic Anemia, and thrombocytopenia associated with chronic hepatitis C infection.
Platelets are essential blood components that help the body form clots and prevent excessive bleeding. When platelet levels become abnormally low, patients may experience symptoms such as easy bruising, prolonged bleeding, nosebleeds, bleeding gums, fatigue, and the appearance of tiny red or purple spots on the skin. TROMLIEVA 25 MG helps stimulate the body's natural platelet production process, reducing the risk of bleeding complications.
Eltrombopag works by activating thrombopoietin receptors found in the bone marrow. These receptors play a key role in the production of platelets. By stimulating these receptors, TROMLIEVA 25 MG encourages the bone marrow to produce more platelets, helping restore healthier platelet levels in the bloodstream.
Unlike platelet transfusions that provide only temporary support, Eltrombopag promotes sustained platelet production by the body's own cells, making it an effective long-term treatment option for many eligible patients.
TROMLIEVA 25 MG is commonly prescribed for:
The medicine may be prescribed when conventional therapies have failed to provide adequate improvement in platelet counts or when long-term platelet management is required.
Manufactured under stringent pharmaceutical quality standards, TROMLIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require regular blood tests, platelet monitoring, liver function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven ability to stimulate platelet production, TROMLIEVA 25 MG has become an important therapeutic option in modern hematology practice.
TROMLIEVA 25 MG (Eltrombopag Olamine Tablets 25 mg) is primarily used to increase platelet counts in patients with specific blood disorders.
The medicine is widely prescribed for patients with chronic ITP who have persistently low platelet counts and an increased risk of bleeding.
Eltrombopag may help improve blood cell production in patients suffering from severe aplastic anemia.
The medicine may be used to increase platelet counts in eligible patients with chronic hepatitis C infection.
Doctors may recommend Eltrombopag as part of treatment plans for selected bone marrow disorders.
The medicine helps maintain platelet levels within a safer range to reduce bleeding risks.
Eltrombopag supports ongoing treatment strategies for chronic low platelet conditions.
The medicine is commonly incorporated into advanced blood disorder treatment protocols.
Eltrombopag belongs to a class of medicines known as Thrombopoietin Receptor Agonists.
TROMLIEVA works by:
This targeted mechanism helps the body naturally produce more platelets and maintain healthier blood clotting function.
Like all medicines, TROMLIEVA 25 MG may cause side effects in some patients. The occurrence and severity of side effects vary among individuals.
Headaches are among the most commonly reported side effects.
Some patients may experience mild nausea during treatment.
Weakness and tiredness may occur during therapy.
Muscle aches and discomfort may develop.
Some individuals may experience pain or stiffness in the joints.
Digestive disturbances may occasionally occur.
Cold-like symptoms may develop in some patients.
Changes in appetite may affect food intake.
Abnormal liver test results may require additional monitoring.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of TROMLIEVA 25 MG (Eltrombopag Olamine Tablets 25 mg) should always be determined by a qualified healthcare professional.
Dosage depends on the specific blood disorder being treated.
Regular platelet monitoring helps determine treatment adjustments.
Patients with liver impairment may require modified dosing.
Doctors may adjust dosage according to platelet count improvements and overall response.
Age, weight, medical history, and concurrent treatments may influence dosage decisions.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, vitamins, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should use this medicine only if specifically advised by a healthcare professional.
It is used to increase platelet counts in patients with chronic immune thrombocytopenia, severe aplastic anemia, and certain cases of hepatitis C-associated thrombocytopenia.
Eltrombopag Olamine is a thrombopoietin receptor agonist that stimulates platelet production in the bone marrow.
It activates thrombopoietin receptors, encouraging the bone marrow to produce more platelets and improve platelet counts.
No. It is not a steroid. It works by stimulating platelet production through thrombopoietin receptor activation.
Yes. By increasing platelet levels, it may help reduce the risk of bleeding complications in eligible patients.
Yes. Routine platelet counts, liver function tests, and medical evaluations are important during treatment.
Treatment duration depends on the patient's condition, treatment response, and healthcare provider's recommendations.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in hematology and blood disorder management.